FLOW (2024) — Trial Summary

FLOW (2024): The FLOW trial evaluated semaglutide, a GLP-1 receptor agonist, for reducing the risk of kidney disease progression in patients with type 2 diabetes and CKD.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.